Earnings Feed
Start Free
C4 Therapeutics, Inc.·4

Feb 18, 5:04 PM ET

Adams Kendra 4

Research Summary

AI-generated summary

Updated

C4 Therapeutics CFO Kendra Adams Receives RSUs, Converts to Shares

What Happened

  • Kendra Adams, Chief Financial Officer of C4 Therapeutics (CCCC), received a 240,000‑share RSU award on Feb 13, 2026 and had previously‑granted RSUs vest and convert to stock on Feb 13–14, 2026.
  • The vesting/conversion produced 34,700 shares (3,750 on 2/13 and 30,950 on 2/14) acquired at $0.00 (these were RSU settlements). The company withheld 17,244 shares to satisfy tax withholding (1,863 on 2/13 and 15,381 on 2/14) at $1.89 per share, totaling about $32,591. Net new shares delivered to Adams = 17,456 shares.
  • These transactions are compensation‑related (awards and RSU settlements), not open‑market purchases or discretionary sales.

Key Details

  • Transaction dates/prices: 2/13/2026 (award of 240,000 RSUs; conversion of 3,750 RSUs @ $0.00; 1,863 shares withheld @ $1.89); 2/14/2026 (conversion of 30,950 RSUs @ $0.00; 15,381 shares withheld @ $1.89).
  • Shares owned after transaction: not specified in the provided filing.
  • Footnotes: F1 = 240,000 RSUs vest per schedule (120,000 vest in three equal annual installments beginning Feb 13, 2027; 120,000 vest in full on Feb 13, 2029 subject to performance). F2 = the converted shares came from earlier RSU grants reported in prior Forms 4. F3 = withheld shares were to satisfy tax withholding and do not represent an open‑market sale by the reporting person.
  • Filing timeliness: Form 4 was filed Feb 18, 2026 for transactions on Feb 13–14, 2026. This appears to be a late filing (Form 4 is generally due within two business days), which delays public transparency.

Context

  • Code meanings: A = Award/Grant; M = Exercise/conversion of a derivative (here, RSUs converting to shares); F = Shares withheld for tax obligations. The M entries reflect RSU settlement (no cash exercise price), not exercise of stock options requiring cash.
  • For retail investors: these entries are routine executive compensation events (grant + RSU vesting and tax withholding). They indicate equity compensation being delivered, not an insider buying or publicly selling to express a market view.